Cargando…

How do serum lipid levels change and influence progression-free survival in epithelial ovarian cancer patients receiving bevacizumab treatment?

BACKGROUND: This study aimed to investigate how serum lipid levels affect epithelial ovarian cancer (EOC) patients receiving bevacizumab treatment and to develop a model for predicting the patients’ prognosis. METHODS: A total of 139 EOC patients receiving bevacizumab treatment were involved in this...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Xiaoyu, Huang, Yong, Li, Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090393/ https://www.ncbi.nlm.nih.gov/pubmed/37064140 http://dx.doi.org/10.3389/fonc.2023.1168996

Ejemplares similares

Real-World Efficacy of Bevacizumab in Patients With Recurrent Epithelial Ovarian Cancer
por: Hung, Jo-Ni, et al.
Publicado: (2022)

Associations of novel serum lipid index with epithelial ovarian cancer chemoresistance and prognosis
por: Li, Yuan, et al.
Publicado: (2023)

Prognostic nomogram that predicts progression-free survival and overall survival of patients with ovarian clear cell carcinoma
por: Li, Jiayi, et al.
Publicado: (2022)

Serum Free Fatty Acids and G-Coupled Protein Receptors Are Associated With the Prognosis of Epithelial Ovarian Cancer
por: Zhang, Lili, et al.
Publicado: (2022)

Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma
por: Tate, Shinichi, et al.
Publicado: (2021)

Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer
por: Mahner, Sven, et al.
Publicado: (2015)

Multiple genetic variants predict the progression-free survival of bevacizumab plus chemotherapy in advanced ovarian cancer: A retrospective study
por: Gao, Jie, et al.
Publicado: (2021)

Case report: Changes in serum bevacizumab concentration in a hemodialysis patient with unresectable colorectal cancer treated with FOLFIRI plus bevacizumab
por: Tanaka, Toshimitsu, et al.
Publicado: (2022)

Predicting Progression-Free Survival Using MRI-Based Radiomics for Patients With Nonmetastatic Nasopharyngeal Carcinoma
por: Shen, Hesong, et al.
Publicado: (2020)

PDCD6 is an independent predictor of progression free survival in epithelial ovarian cancer
por: Su, Dan, et al.
Publicado: (2012)

Race and Ethnicity Influence Survival Outcomes in Women of Caribbean Nativity With Epithelial Ovarian Cancer
por: Schlumbrecht, Matthew, et al.
Publicado: (2020)

Survival prognosis model for elderly women with epithelial ovarian cancer based on the SEER database
por: Zhou, Yingping, et al.
Publicado: (2023)

MRI radiomics predicts progression-free survival in prostate cancer
por: Jia, Yushan, et al.
Publicado: (2022)

A machine learning approach applied to gynecological ultrasound to predict progression-free survival in ovarian cancer patients
por: Arezzo, Francesca, et al.
Publicado: (2022)

Real-World Impact of Survival by Period of Diagnosis in Epithelial Ovarian Cancer Between 1990 and 2014
por: Wu, San-Gang, et al.
Publicado: (2019)

Corrigendum: MRI radiomics predicts progression-free survival in prostate cancer
por: Jia, Yushan, et al.
Publicado: (2023)

Integrated multi-dimensional deep neural network model improves prognosis prediction of advanced NSCLC patients receiving bevacizumab
por: Li, Butuo, et al.
Publicado: (2023)

Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience
por: Wu, Pei-Ying, et al.
Publicado: (2020)

Systematic Review and Meta-Analysis of Correlation of Progression-Free Survival-2 and Overall Survival in Solid Tumors
por: Chowdhury, Simon, et al.
Publicado: (2020)

Modeling Sarcopenia to Predict Survival for Patients With Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy
por: Hua, Xin, et al.
Publicado: (2021)

Can 9q34.2 rs633862 polymorphism predict survival in epithelial ovarian cancer?
por: Jiang, Rong, et al.
Publicado: (2017)

Circulating metabolites associated with tumor hypoxia and early response to treatment in bevacizumab-refractory glioblastoma after combined bevacizumab and evofosfamide
por: Lodi, Alessia, et al.
Publicado: (2022)

Progression-Free Survival, Prognostic Factors, and Surgical Outcome of Spheno-Orbital Meningiomas
por: Masalha, Waseem, et al.
Publicado: (2021)

Biomarker Assessment of Homologous Recombination Deficiency in Epithelial Ovarian Cancer: Association With Progression-Free Survival After Surgery
por: Yi, Huan, et al.
Publicado: (2022)

SIRT6 Is Involved in the Progression of Ovarian Carcinomas via β-Catenin-Mediated Epithelial to Mesenchymal Transition
por: Bae, Jun Sang, et al.
Publicado: (2018)

Prognostic Value of Elevated Pre-treatment Serum CA-125 in Epithelial Ovarian Cancer: A Meta-Analysis
por: Wang, Qingyi, et al.
Publicado: (2022)

Delta radiomics model for the prediction of progression-free survival time in advanced non-small-cell lung cancer patients after immunotherapy
por: Xie, Dong, et al.
Publicado: (2022)

Radiomics Analysis of PET and CT Components of (18)F-FDG PET/CT Imaging for Prediction of Progression-Free Survival in Advanced High-Grade Serous Ovarian Cancer
por: Wang, Xihai, et al.
Publicado: (2021)

Epithelial–Mesenchymal Transition in Ovarian Carcinoma
por: Davidson, Ben, et al.
Publicado: (2012)

c-MYC and Epithelial Ovarian Cancer
por: Reyes-González, Jeyshka M., et al.
Publicado: (2021)

Dynamic contrast-enhanced magnetic resonance imaging-based radiomics for the prediction of progression-free survival in advanced nasopharyngeal carcinoma
por: Li, Wen-zhu, et al.
Publicado: (2022)

Histological Characteristics and Early-Stage Diagnosis Are Associated With Better Survival in Young Patients With Epithelial Ovarian Cancer: A Retrospective Analysis Based on Surveillance Epidemiology and End Results Database
por: Huang, Yue, et al.
Publicado: (2020)

Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer
por: French, Juliet D., et al.
Publicado: (2016)

Exploration of Potential Diagnostic Value of Protein Content in Serum Small Extracellular Vesicles for Early-Stage Epithelial Ovarian Carcinoma
por: Li, Pu, et al.
Publicado: (2021)

LAPS score for individualized treatment of advanced EGFR-mutated non-small cell lung cancer receiving EGFR-TKIs with or without bevacizumab
por: Wu, Yahua, et al.
Publicado: (2023)

Association between lipid variability and the risk of mortality in cancer patients not receiving lipid-lowering agents
por: Kim, Seohyun, et al.
Publicado: (2023)

Impact of genetic variants involved in the lipid metabolism pathway on progression free survival in patients receiving bevacizumab-based chemotherapy in metastatic colorectal cancer: a retrospective analysis of FIRE-3 and MAVERICC trials
por: Wang, Jingyuan, et al.
Publicado: (2023)

Baseline serum uric acid level is associated with progression-free survival, disease control rate, and safety in postoperative patients with colorectal cancer treated by FOLFOX, FOLFIRI, or XELOX
por: Zhang, Xi, et al.
Publicado: (2022)

MRI Radiomic Features: A Potential Biomarker for Progression-Free Survival Prediction of Patients With Locally Advanced Cervical Cancer Undergoing Surgery
por: Cai, Mengting, et al.
Publicado: (2021)

Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors
por: Hsu, Ping-Chih, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bq5g93vrtp0a8pb6dh6l68a446